528205 Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem

528205
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Key Specifications Table

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      528205-50UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 50 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewPAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.
          Catalogue Number528205
          Brand Family Calbiochem®
          SynonymsPAI-1
          References
          ReferencesVaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
          Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
          Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
          Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
          Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
          Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
          Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
          Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
          Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.
          Product Information
          ATP CompetitiveN
          FormLiquid
          FormulationIn 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
          ReversibleN
          Applications
          Biological Information
          Biological activity≥90% by uPA assay
          Primary TargetTissue plasminogen activator (tPA) and urokinase (uPA)
          Purity≥98% by SDS-PAGE
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem Certificates of Analysis

          TitleLot Number
          528205

          References

          Reference overview
          Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
          Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
          Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
          Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
          Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
          Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
          Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
          Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
          Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-August-2008 RFH
          SynonymsPAI-1
          DescriptionPrimary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is synthesized by vascular epithelium and hepatocytes. Used as a marker for acute myocardial infarction and in the diagnosis of several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Shown to have a role complimentary to that of α2-anti-plasmin. Elevated levels are found in subjects with accelerated coronary artery disease. PP1 activity may limit the extent of metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane. May serve as an independent and strong prognosticator in breast cancer patients. Patients having elevated levels of PAI-1 in their primary tumors are more prone to relapse. Can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified free of the inactive material.
          FormLiquid
          FormulationIn 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
          Purity≥98% by SDS-PAGE
          Biological activity≥90% by uPA assay
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Toxicity Standard Handling
          ReferencesVaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
          Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
          Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
          Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
          Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
          Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
          Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
          Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
          Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.